FRAGMENT 176-191 PEPTIDE

Fragment 176-191

The fragment 176-191 is a fragment of the Human Growth Hormone amino acid sequence which is being invesstigated for its lipolytic effects.

View Peptide Purity Reference Chart

This information is for educational purposes only. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA)

References

1. C. H. Gravholt, O. Schmitz, L. Simonsen, J. Bülow, J. S. Christiansen, and N. MØller, “Effects of a physiological GH pulse on interstitial glycerol in abdominal and femoral adipose tissue,” Am. J. Physiol. - Endocrinol. Metab., 1999.
2. J. Rodríguez-Arnao, A. Jabbar, K. Fulcher, G. M. Besser, and R. J. M. Ross, “Effects of growth hormone replacement on physical performance and body composition in GH deficient adults,” Clin. Endocrinol. (Oxf)., 1999.
3. G. A. Aguirre, J. R. Ita, R. G. Garza, and I. Castilla-Cortazar, “Insulin-like growth factor-1 deficiency and metabolic syndrome,” J. Transl. Med., 2016.
4. M. Beauville et al., “Effect of long-term administration in GH-deficient adults on fat cell epinephrine response,” Am. J. Physiol. - Endocrinol. Metab., 1992.
5. J. Dietz and J. Schwartz, “Growth hormone alters lipolysis and hormone-sensitive lipase activity in 3T3-F442A adipocytes,” Metabolism, 1991.
6. M. Ridderstråle and H. Tornqvist, “Effects of tyrosine kinase inhibitors on tyrosine phosphorylations and the insulin-like effects in response to human growth hormone in isolated rat adipocytes,” Endocrinology, 1996.
7. M. A. Heffernan, W. J. Jiang, A. W. Thorburn, and F. M. Ng, “Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism,” Am. J. Physiol. - Endocrinol. Metab., 2000.
8. F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., 2000.
9. R. Ferrer-Lorente, C. Cabot, J. A. Fernández-López, and M. Alemany, “Combined effects of oleoyl-estrone and a β3-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats,” Life Sci., 2005.
10. L. Poekes, N. Lanthier, and I. A. Leclercq, “Brown adipose tissue: A potential target in the fight against obesity and the metabolic syndrome,” Clinical Science. 2015.
11. A. M. Cypess et al., “Activation of human brown adipose tissue by a β3-adrenergic receptor agonist,” Cell Metab., 2015.
12. Stier, “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans,” J. Endocrinol. Metab., 2013.
13. J. M. Chan et al., “Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study,” Science (80-. )., 1998.
14. S. E. Hankinson et al., “Circulating concentrations of insulin-like growth factor-I and risk of breast cancer,” Lancet, 1998.
15. M. A. Valentino, J. E. Lin, and S. A. Waldman, “Central and peripheral molecular targets for antiobesity pharmacotherapy,” Clinical Pharmacology and Therapeutics. 2010.

Storage: Lyophilized peptide should be stored at -20°C (freezer), and the reconstituted peptide solution at 4°C (refrigerated). Do not freeze once reconstituted.